好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Emergence of Endovascular Treatment Only Centers for Treatment of Intracranial Aneurysms in United States
Interventional Neurology
P04 - (-)
086
BACKGROUND: Due to availability of new technology has resulted in very few aneurysms that cannot be treated with endovascular treatment. Some centers have started offering only endovascular treatment to patients with intracranial aneurysms (endovascular treatment only center [ETOC]).
DESIGN/METHODS: We determined the proportion of endovascular treatment only centers in United States using Nationwide Inpatient Survey (NIS) data files from 2010. We compared various in-hospital outcomes between ETOCs and non-ETOCs. The outcomes studied were favorable outcome (discharge destination to home/self care), in-hospital mortality, length of stay, and hospital charges.
RESULTS: Out of 85 hospitals performing endovascular treatment of un-ruptured aneurysms, 13 (15%) were categorized as ETOCs. Out of the 10447 patients with un-ruptured aneurysms, 1245 (12%) were treated at ETOCs. There were no differences in mean age, gender, and race/ethnicity between patients treated at ETOCs and non-ETOCs. ETOCs were more likely to be non-teaching hospitals (55% versus 8%, p=0.02). The rate of in-hospital mortality (1.2% versus 1.8%) and favorable outcome (88% versus 84%) was similar in patients treated at ETOCs and non ETOC hospitals. The mean hospitalization charges ($125,563卤121,515 versus $ 129,721卤123,265) were similar but length of stay (4卤7 versus 6卤10 days, p<0.0001) was significantly shorter among patients treated at ETOCs.
CONCLUSIONS: The recent emergence of ETOCs and provision of treatment with comparable outcomes and shorter length of stay at these hospitals may change the pattern of intracranial aneurysm management in United States.
Authors/Disclosures
Farhan Siddiq, MD
PRESENTER 		Dr. Siddiq has nothing to disclose.
No disclosure on file
No disclosure on file
Tara Nazareth (Mallinckrodt Pharmaceuticals) No disclosure on file
Hamza I. Maqsood, MD (Dept of Neurology) Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.